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Repurposed agents in the Alzheimer’s
disease drug development pipeline
Justin Bauzon1, Garam Lee2 and Jeffrey Cummings2,3*
Abstract
Background: Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials
have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the
pharmaceutical development process is both time-consuming and costly. Drug repurposing provides an
opportunity to accelerate this process by investigating the AD-related effects of agents approved for other
indications. These drugs have known safety profiles, pharmacokinetic characterization, formulations, doses, and
manufacturing processes.
Methods: We assessed repurposed AD therapies represented in Phase I, Phase II, and Phase III of the current AD
pipeline as registered on ClinicalTrials.gov as of February 27, 2020.
Results: We identified 53 clinical trials involving 58 FDA-approved agents. Seventy-eight percent of the agents in
trials had putative disease-modifying mechanisms of action. Of the repurposed drugs in the pipeline 20% are
hematologic-oncologic agents, 18% are drugs derived from cardiovascular indications, 14% are agents with
psychiatric uses, 12% are drug used to treat diabetes, 10% are neurologic agents, and the remaining 26% of drugs
fall under other conditions. Intellectual property strategies utilized in these programs included using the same drug
but altering doses, routes of administration, or formulations. Most repurposing trials were supported by Academic
Medical Centers and were not funded through the biopharmaceutical industry. We compared our results to a
European trial registry and found results similar to those derived from ClinicalTrials.gov.
Conclusions: Drug repurposing is a common approach to AD drug development and represents 39% of trials in
the current AD pipeline. Therapies from many disease areas provide agents potentially useful in AD. Most of the
repurposed agents are generic and a variety of intellectual property strategies have been adopted to enhance their
economic value.
Keywords: Alzheimer’s disease, Clinical trials, Repurposing, Dose, Formulation, Disease-modification
Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder with a rising prevalence due to the global
increase in the aging population [1]. It is estimated that
one in 85 people will be living with an AD diagnosis by
2050 [2]. An urgent need exists to identify effective in-
terventions that will combat this disabling and ultimately
fatal disease. Attempts to find new therapies for AD
have been made by academic centers and biopharma-
ceutical companies: identifying new chemical entities,
optimizing them for human use, and investigating their
effects in clinical trials. However, the lack of an ap-
proved drug for AD by the Food and Drug Administra-
tion (FDA) since 2003 demonstrates the complexity of
this objective [3].
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Efforts to produce new treatments for AD are focused
primarily on identifying new compounds that may im-
prove symptoms, slow disease progression, delay the on-
set, or ultimately prevent the disease. An alternative
approach to advancing new treatments is the develop-
ment of drugs approved for a non-AD-related indication
that may impact the biology of AD through on-target or
off-target mechanisms. This repurposing strategy has
succeeded in other conditions and has promise for AD
since many FDA-approved agents exhibit AD-relevant
effects evident through in vitro, animal, epidemiologic,
and observational studies [4–9].
To better understand repurposing in the AD drug de-
velopment process, we conducted an analysis of all on-
going AD clinical trials involving FDA-approved drugs.
We analyzed trial data reported on ClinicalTrials.gov, a
comprehensive US government database with mandated
registration of all clinical trials conducted within the US.
We examined all currently ongoing trials that involved
repurposed agents and compared this to all drugs in the
AD pipeline [10–14]. We also compared ongoing trial
activity of repurposed AD drugs as reported on the
European Union Clinical Trials Register (EUCTR). Our
goal was to examine how repurposing efforts in the AD
drug pipeline compares to overall drug development ac-
tivity in the United States (US) and international pipe-
lines and to provide insight into repurposing as a drug
development strategy.
Methods
This study is based on the activity of clinical trials re-
ported on ClinicalTrials.gov. By US law, all clinical trials
conducted within the US must be registered within 21
days of the enrollment of the first participant [15, 16].
ClinicalTrials.gov is a comprehensive and valid data
source for the study of clinical trials conducted in the
US. Most, but not all, non-US trials are registered on
clinicaltrials.gov; Phase I trials conducted outside the US
are often not registered and our findings may underre-
present the agents populating global Phase I efforts.
We used a previously constructed trial database that
included the data of interest [10–14] and report on all
trials currently testing repurposed agents in Phases I, II,
and III. The results reported here are based on trials reg-
istered on ClinicalTrials.gov as of February 27, 2020. We
used ClinicalTrials.gov labeling and included trials that
were recruiting, active but not recruiting, enrolling by
invitation, and not yet recruiting. We do not include tri-
als of stem cell therapies among the interventions
reviewed.
Our focus on repurposed agents places an importance
on drugs with an FDA-approved indication(s). Agents
were considered to be repurposed based on the informa-
tion recorded on Drugs@FDA (fda.gov/drugsatfda), a US
government database containing drug products approved
since 1939 that is updated daily [17]. The approved use
for each drug was determined by the most recent label
provided by Drugs@FDA. Some drugs have more than
one FDA-approved indication, and this is noted.
Agents were further classified based on the therapeutic
area for which each drug is prescribed as determined by
its approved indication. Based on this classification, we
examined the therapeutic area origin of agents being
studied across all AD trials. Some agents are being stud-
ied in multiple ongoing trials; we defined these agents as
“unique” agents. Varieties of a particular compound seen
in two or more trials (i.e., dosing, routes of administra-
tion) were noted.
Some trials are investigating multiple repurposed
drugs in separate treatment arms (e.g., telmisartan vs
perindopril) or in combination (e.g., losartan, amlodi-
pine, and atorvastatin as a single treatment). For the
purposes of this study, we treat the former as separate
therapeutic trial agents; the latter is considered a single
agent with respect to its clinical trial because the intent
of the trial is to study the effects of the fixed combin-
ation as a single therapy.
A drug’s putative mechanism of action (MOA) in AD
was determined from the information on ClinicalTrials.
gov or from a comprehensive review of the literature for
the specific agent. We grouped the mechanisms into
disease-modifying therapies (DMTs) or symptomatic
agents. The latter is further divided into cognitive-
enhancers or those that address neuropsychiatric and
behavioral symptoms. We identified an agent as a DMT
when the purpose of the intervention was to modify the
underlying disease biology and to delay the onset or slow
the progression of the disease. DMTs were divided into
those targeting amyloid-related targets, tau-related
mechanisms, and those with “other” mechanisms (i.e.,
neuroprotection, anti-inflammation, metabolic effects).
The distinction between symptomatic agents and DMTs
can be arbitrary and some agents may have both proper-
ties. For the purposes of this study, we chose what ap-
pears to be the principal MOA.
We retrospectively compare current repurposing trial
data with historical data from previous AD pipeline re-
views, starting from 2016 onward [10–14]. We used
identical methodology to ascertain inclusion of clinical
trials as detailed above.
Our study analyzes parallel activity between the US
and European AD pipelines using trial information re-
ported on the EUCTR. This public register enables ac-
cess to data from the European Union Drug Regulating
Authorities Clinical Trials (EudraCT) database, which
contains protocols and results of studies conducted in
the European Union (EU) or the European Economic
Area (EEA). We used EUCTR to query Phase I, Phase II,
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and Phase III AD trials with ongoing status recorded as
of February 27, 2020. We distinguish clinical trials exclu-
sive to the EU/EEA from overlap studies running con-
currently in the US.
Results
Overview
There are 58 total repurposed drugs in 53 clinical trials
as reported on ClinicalTrials.gov. We identified 15
agents in 12 trials in Phase III, 33 agents in 32 trials in
Phase II, and 10 agents in nine trials in Phase I. Of these
trials, six agents were in Phase II/III trials and two
agents were in Phase I/II trial. Several trials have more
than one agent; some drugs are being studied across
multiple trials.
Analysis of the FDA-approved indications of all
repurposed drugs in the pipeline showed that 20% are
hematologic-oncologic agents, 18% cardiovascular
agents, 14% are psychiatric agents, 12% are antidia-
betic treatments, 10% are drugs for other neurologic
disorders, and the remaining 26% of drugs are derived
from other therapeutic area categories. Repurposed
psychiatric drugs in Phase III trials represent 50% of
all agents being assessed for the treatment of neuro-
psychiatric symptoms in AD. Half of all cardiovascu-
lar agents under study are in Phase III trials. The
majority of the pipeline’s hematologic-oncologic, anti-
diabetic, and neurologic agents are in Phase II trials
(70, 67, and 67%, respectively). Phase II has more
repurposed agents than Phase I and Phase III com-
bined. Figure 1 shows the classification of all
repurposed drugs by FDA-approved indications within
their respective clinical phases.
Review of the AD-related MOAs of all agents shows
that 78% are being developed as DMTs, 16% are symp-
tomatic agents addressing neuropsychiatric and behav-
ioral changes, and 7% are cognitive enhancers (Table 1).
Escitalopram is being investigated separately as a cogni-
tive enhancer in Phase I and as a neuropsychiatric agent
in Phase III. Among DMT trials, the agents are derived
primarily from hematologic-oncologic, cardiovascular,
and antidiabetic indications (26, 18, and 16%, respect-
ively). In contrast, symptomatic agents are derived
mostly from treatments addressing psychiatric illness
(50%). Figure 2 shows the repurposed agents’ AD-related
MOAs.
Unique repurposed agents
There are 50 unique repurposed drugs (defined as drugs
represented at least once from the 58 total in the pipe-
line) that are under study among all AD pipeline trials.
Twenty percent are hematologic-oncologic agents, 18%
are cardiovascular agents, 14% are psychiatric agents,
12% are antidiabetic agents, 10% are neurologic drugs,
and the remaining 26% of treatments were used in other
categories. Figure 3 provides a graphical summary of the
classifications of all unique repurposed agents repre-
sented in the current AD pipeline.
The agent most represented among all trials is leveti-
racetam (four Phase II trials, one Phase III trial). Telmi-
sartan, montelukast, escitalopram, and valacyclovir are
each in multiple Phase II and Phase III trials. A propriety
Fig. 1 Classification of repurposed agents by their FDA-approved indications (ClinicalTrials.gov as of February 27, 2020)
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low-dose formulation of levetiracetam (AGB101, which
is 1/15th of the original dose) is being investigated in
Phase II and Phase III trials.
Phase III
In Phase III trials, there are 15 repurposed agents in 12 tri-
als (Table 2); this represents one-third of all Phase III trials
in the AD pipeline [14]. These include eight DMTs, one
cognitive-enhancer, and six agents addressing behavioral
symptoms. Among DMT agents, one had amyloid-related
targets, five had anti-inflammatory MOAs, four were con-
sidered metabolic, and two were neuroprotective agents.
Therapeutic areas represented among the repurposed
agents included five cardiovascular drugs, four with psy-
chiatric indications, three neurological drugs, one
hematologic-oncologic agent, one antidiabetic agent, and
one pulmonary agent. Among these drugs, sedative-
hypnotics were the most common.
In Phase III, there were two prevention trials with cog-
nitively normal (preclinical) participants; three trials of
patients with prodromal AD/mild cognitive impairment
(MCI); five trials of patients with mild to moderate AD;
and two trials of patients with mild to moderate/severe
AD.
Phase II
Phase II of the AD pipeline has 32 trials involving 33
repurposed agents (Table 3); this is 44% of all AD trials
in Phase II [14]. Of the repurposed agents, there were 27
DMTs, one cognitive-enhancing agent, and three drugs
for behavioral symptoms. Among the DMTs, three in-
volve amyloid targets, one addresses tau-related targets,
one has a mechanism relevant to both amyloid- and tau-
related targets, and 22 have other MOAs (e.g., neuropro-
tection, metabolic, or anti-inflammatory). Of the symp-
tomatic agents, all four are neurotransmitter-based.












Total # of agents
(%)
Hematologic-oncologic 10 – – – 10 (20.0)
Cardiovascular 7 1 1 – 9 (18.0)
Psychiatric 1 1 4 1 7 (14.0)
Antidiabetic 6 – – – 6 (12.0)
Neurologic 3 – 2 – 5 (10.0)
Infectious disease 3 – – – 3 (6.0)
Anti-inflammatory 2 – – – 2 (4.0)
Genetics 1 – – – 1 (2.0)
Cannabinoid – – 1 – 1 (2.0)
Hormonal 1 – – – 1 (2.0)
Immunologic 1 – – – 1 (2.0)
Alkaloid – 1 – – 1 (2.0)
Pulmonary 1 – – – 1 (2.0)
Nutraceutical 1 – – – 1 (2.0)
Vitamin 1 – – – 1 (2.0)
TOTAL 38 3 8 1 50 (100.0)
Fig. 2 Percentage of repurposed agents currently under study by mechanisms of action (ClinicalTrials.gov as of February 27, 2020)
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Therapeutic areas of Phase II repurposed agents com-
prise hematologic-oncologic agents (seven), neurologic
drugs (six), cardiovascular drugs (four), antidiabetic
agents (four), and other classes (e.g., cannabinoid, alkal-
oid; 12 total). Anticonvulsants were the most repre-
sented drug class in Phase II.
There is one prevention trial; 19 trials of patients with
prodromal/MCI or prodromal/mild-AD; 11 trials in
mild-moderate AD; and one trial of patients with mild-
moderate/severe AD. Among DMT trials, there is one
prevention trial with cognitively normal participants, 17
for prodromal/mild AD, and eight for participants with
mild-moderate AD.
Phase I
There are ten repurposed agents among nine Phase I tri-
als (Table 4), which is 33% of Phase I trials in the pipe-
line [14]. Of these, there are eight DMTs and two
cognitive enhancers. No agents addressing neuropsychi-
atric symptoms are represented in the Phase I pipeline.
Of the DMTs in Phase I, one agent is directed at
amyloid-related targets while seven have other MOAs
(e.g., neuroprotection, metabolic, or anti-inflammatory).
No tau-related repurposed agents are under investiga-
tion in Phase I of the current pipeline.
In Phase I, repurposed agents include three psychiatric
drugs, two hematologic-oncologic agents, one cardiovas-
cular drug, one antidiabetic agent, and three agents in
other drug classes (e.g., anti-inflammatory drug, infec-
tious disease agent).
Trial sponsors
Across all trials of repurposed agents, 9% are sponsored
by the biopharma industry, 79% by Academic Medical
Centers (with funding from the National Institutes of
Health, industry, and/or other entities such as a consor-
tium or a philanthropic foundation), and 11% by others.
Table 5 shows sponsors for each phase of development.
Repurposed agents in the pipeline from 2016 to 2020
Table 6 summarizes the number of repurposing trials in
previous annual AD pipeline reports [10–14]. Since
2016, the number of trials involving repurposed agents
has increased by 89%. The number of trials has grown
each year, with the greatest rate of increase occurring
between 2019 and 2020 (23% growth). Between 2016
and 2020, repurposed DMT trials have increased 180%;
repurposed trials focused on symptom-reduction have
decreased by 67%.
Phase I trials of repurposed agents have increased
125% since 2016; Phase II and Phase III trials have risen
88% and 71%, respectively. DMT trials of repurposed
agents currently make up 79% of all repurposed agents
in the current pipeline (up from 54% in 2016; Fig. 4).
Repurposed agents in the European AD pipeline
Out of 138 AD trials with an ongoing status registered
with the EUCTR, we identified 14 trials involving 14
FDA-approved drugs (Table 7). Eleven of these were
dual-registered with the US and EU/EEA databases. Five
trials were in Phase III and nine were in Phase II. Six
had a completed or terminated status when compared to
the information listed on ClinicalTrials.gov. Three trials
were registered exclusively with the EUCTR: epoetin
alfa, levodopa-carbidopa, and cannabidiol.
There were six DMTs, five cognitive-enhancing
agents, and three drugs addressing neuropsychiatric
symptoms among the repurposed agents. Therapeutic
Fig. 3 Classification of the therapeutic areas of repurposed agent currently under study (ClinicalTrials.gov as of February 27, 2020)
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Table 2 Repurposed agents currently in Phase III in the Alzheimer’s disease development pipeline (as of February 27, 2020)
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areas represented included four neurologic drugs, two
hematologic-oncologic agents, one drug with pulmon-
ary indications, and one antidiabetic agent.
Discussion
Drug repurposing provides the unique opportunity to
significantly shorten the development period of a thera-
peutic candidate for AD. These agents have been exten-
sively assessed for pharmacokinetic properties and
toxicities normally required in nonclinical and Phase 1
stages of development. Over half of all agents fail in de-
velopment for these two reasons, and repurposing cir-
cumvents these challenges [18]. FDA-approved drugs
have already undergone human trials, and safety, effi-
cacy, and adverse event profiles are known. The results
of previous trials may suffice to bypass nonclinical stages
and earlier clinical phases of study; this has the advan-
tage of foregoing the financial and time-costs associated
with a drug development program. Total costs for devel-
oping a new agent may be as high as $5.7 billion with
$1.66 billion required for non-clinical studies and $1.19
billion for Phase I [19]. Total development costs may be
reduced by 50% compared to the cost of developing a
new chemical entity.
FDA-approved agents have been optimized for the ori-
ginal indication. Different doses might be needed, and
different adverse event profiles may occur in an AD
population compared to other populations for which the
agent was originally developed. Some steps in the devel-
opment process might be repeated to account for these
contingencies. Repurposed agents are often generic and
have limitations on intellectual property rights that com-
promise attracting investments that could propel their
development [20].
Examination of the repurposed agents in the current
AD pipeline revealed that DMT trials were chiefly based
on agents derived from hematologic-oncologic (tyrosine
kinase inhibitors), cardiovascular (angiotensin II receptor
antagonists, angiotensin-converting enzyme inhibitors),
and neurologic indications (anticonvulsants), as well as
diabetes. Growing evidence supports the association be-
tween the key pathologic changes these drugs target and
the underlying biology of AD [21–24]. The links be-
tween dementia-related symptoms and the abnormal ac-
tivation of tyrosine kinase pathways, cardiovascular
disease, and impaired insulin sensitivity are reflected by
the presence of these agents in the pipeline of repur-
posed drugs. With increasing knowledge of these pro-
cesses in AD, repurposing may comprise a precision
medicine approach to AD therapeutics [25]. A prepon-
derance of psychiatric compounds comprise the symp-
tomatic agent class, and the vast majority (including
some non-antipsychotics) are aimed at alleviating AD-
associated agitation. This may show a priority in the
field to identify treatments for a distressing aspect of AD
for patients and caregivers. These trials were facilitated
by the development of new diagnostic criteria for agita-
tion that assist in patient identification and outcome de-
termination [26].
Certain repurposed candidates may offer therapeutic
benefits without directly engaging AD targets. Reduced
cerebral blood flow correlates with AD pathology [27]. A
pilot study has suggested that the antiplatelet agent,
cilostazol (NCT02491268), may slow cognitive decline
through pleiotropic effects, including regional enhance-
ment of cerebral perfusion [28–30]. Some drugs target
the role of neuroinflammation in AD: inflammation af-
fecting the function of the blood-brain barrier is a com-
ponent of interest in two trials of montelukast
(NCT03402503, NCT03991988, [31, 32]). Trialists study-
ing rifaximin (NCT03856359) posit an improvement in
cognitive function by reduction in pro-inflammatory cy-
tokines and ammonia levels [32].
Repurposing agent trials make up 39% of the total AD
pipeline in 2020 (compared to 24% in 2016). Phase II
has the largest number of trials—in both repurposing tri-
als and in the overall pipeline (60 and 55%, respectively).
This likely results from entry of repurposed agents dir-
ectly into Phase II or Phase I/II. DMT trials comprise
approximately 79% of the 2020 AD pipeline, compared
to 75% when looking at the subset of repurposed agents.
Although amyloid is the most common specific target in
Phase II and Phase III DMT trials overall, the majority
of repurposed DMTs involve tau targets.
Forty-six percent of all AD trials are funded at least
in part by biopharmaceutical industry sources. In con-
trast, the majority of repurposed trials (79%) receive
partial or complete funding from Academic Medical
Centers and only 9% are sponsored by the bio-
pharmaceutical industry. This reflects the challenges
of obtaining intellectual property protection for repur-
posed agents that discourage for-profit enterprises
Table 2 Repurposed agents currently in Phase III in the Alzheimer’s disease development pipeline (as of February 27, 2020)
(Continued)














Abbreviations: DMT disease-modifying therapy, DM dextromethorphan
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Table 3 Repurposed agents currently in Phase II in the Alzheimer’s disease development pipeline (as of February 27, 2020)































Cilostazol II Neuroprotective Reduce accumulation of







































































Insulin glulisine II Metabolic Enhance cell signaling and
growth; promote neuronal
metabolism (DMT)








Anti-neoplastic Multiple myeloma Hematologic-
oncologic
NCT04032626
Levetiracetam II Neuroprotective Reduce amyloid induced
neuronal hyperactivity
(DMT)









Levetiracetam II Neuroprotective Reduce amyloid induced
neuronal hyperactivity
(DMT)







Levetiracetam II Neuroprotective Reduce amyloid induced
neuronal hyperactivity
(DMT)







Levetiracetam II Neuroprotective Reduce amyloid induced Anticonvulsant Adjunct therapy for Neurologic NCT03461861
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Table 3 Repurposed agents currently in Phase II in the Alzheimer’s disease development pipeline (as of February 27, 2020)
(Continued)
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from exercising this development pathway. The obser-
vation emphasizes the importance of Academic Med-
ical Centers and federal and philanthropic funding in
the AD drug development ecosystem.
A variety of strategies are being assessed to try to
secure intellectual property positions for repurposed
agents. Using different doses relative to an agent’s
original indication is one approach and depends on
the drug exposure required for each indication. This
strategy is exemplified by the HOPE4MCI study
(NCT03486938), which is using one-tenth of the dose
of levetiracetam used for anticonvulsant purposes.
Another approach is the use of novel formulations of
an agent. Insulin glulisine (NCT02503501) is a rapid-
acting version of the insulin; a long-acting form
(NCT01595646) was developed for trials in AD [33].
Montelukast is being investigated as a cognitive en-
hancer in two separate trials (NCT03991988,
NCT03402503) using an oral tablet and a buccal film
patch, respectively. This highlights the opportunity to
develop novel delivery mechanisms for repurposed
agents as a means of enhancing efficacy and securing
intellectual property rights.
The marked increase in repurposing may reflect the
recent efforts aimed at elucidating the benefits of repur-
posing as a strategy in AD drug development [7, 34].
Funding from federal, advocacy, and philanthropic
sources disproportionately support trials of repurposed
agents and this may have driven the increase in repur-
posing. Repurposing may have been accelerated by ad-
vances in methodologies that are being used to identify
AD-efficacious pharmaceuticals that include phenotypic
or high content screening, in silico techniques, bioinfor-
matic or computational strategies, and medical genetic-
based approaches [9, 35–39]. Electronic health records
may provide evidence of beneficial effects on AD or
other neurodegenerative disorders by therapies approved
for other indications and represent another means for
discovering repurposing agents [39, 40]. The effects of
long-term exposure to these agents, however, may not
Table 3 Repurposed agents currently in Phase II in the Alzheimer’s disease development pipeline (as of February 27, 2020)
(Continued)
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be recapitulated in the 18–24months of most current
AD trials.
Between 2016 and 2020, 20 trials of repurposed agents
reached a “completed” status while four were “termi-
nated” for various reasons. Post hoc analysis of a pilot
Phase II Metformin study (NCT01965756) found the
agent to be safe and well-tolerated, with improvements
in executive function [41]. In another study, a short
course of NewGam 10% IVIG (intravenous immuno-
globulin; NCT01300728) given during the mild cognitive
impairment (MCI) stage of AD decreased brain atrophy
and ameliorated cognitive decline, but beneficial effects
did not persist after 2 years [42]. A phase I study
(NCT01780519) found that lorazepam may unmask pre-
symptomatic cognitive dysfunction in individuals with
underlying genetic risk for AD [43]. Primary outcome
Table 4 Repurposed agents currently in Phase I in the Alzheimer’s disease development pipeline (as of February 27, 2020)
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analyses of the NILVAD study (NCT02017340) failed to
show any treatment benefit with nilvadipine when com-
pared to the matched placebo population, though the
drug was found to be safe and well-tolerated [44]. The
AMBAR study by Grifols (NCT01561053) offers a novel
approach to potential AD treatment via therapeutic al-
bumin replacement with or without immunoglobulin
[45]. Outcome analyses revealed a statistically significant
61% decrease in progression of moderate AD who re-
ceived treatment. None of the trial “failures” results from
problems associated with safety or tolerability, which
may be indicative of the extensive studies repurposed
agents have already undergone.
A single repurposed compound may target different
outcomes; escitalopram is being studied simultaneously
in trials for agitation and for improvements in cognition
(NCT03108846, NCT03274817). Combinations of FDA-
approved drugs represent another approach to repurpos-
ing; ALZT-OP1 (NCT02482324) uses a two-part com-
bination of repurposed agents—a mast-cell stabilizer
(cromolyn) and the non-steroidal anti-inflammatory
agent ibuprofen. A combination of losartan, amlodipine,
and atorvastatin is a combination trial (NCT02913664)
involving repurposed agents to address the vascular di-
mensions of AD.
We assessed repurposing in the EUCTR and compared
it to the analyses of ClinicalTrials.gov. Using the same
criteria used to query the US governmental database, we
found that repurposing trials make up approximately
10% of all ongoing EU/EEA AD trials (in contrast to
39% in the US AD pipeline). Similar to the US pipeline,
the majority of trials (64%) are in Phase II and involve
DMT agents (43%). The majority of agents identified in
the EU/EEA trials were among the agents identified in
ClinicalTrials.gov; only three trials were unique to the
EUCTR.
Some major discrepancies were encountered when
comparing both trial registers. Six of the 14 EUCTR tri-
als, or 43%, were found to have a “completed” or “termi-
nated” status on ClinicalTrials.gov (Table 7). Inaccurate
reporting of dual-registered trials on EUCTR is a preva-
lent issue [46], which may in part reflect the register’s
reliance on sponsors to manually enter study results
onto the EudraCT database. Suboptimal completion of
RCT protocols and results may lead to overestimates of
trial activity [47–50].
Table 5 Trial sponsor for repurposed agents by phase of drug development (as of February 27, 2020)
Sponsor Phase I Phase II Phase III Total (%)
Academic Medical Centers 6 14 4 24 (45.3)
Biopharma 0 2 3 5 (9.4)
NIH 1 0 0 1 (1.9)
NIH and Academic Medical Centers 0 4 2 6 (11.3)
NIH and consortium 0 1 0 1 (1.9)
NIH and Industry 0 0 1 1 (1.9)
Academic Medical Centers and Industry 0 2 0 2 (3.8)
Academic Medical Centers and Foundation 1 4 0 5 (9.4)
Academic Medical Centers, Industry, and NIH 0 0 1 1 (1.9)
Other combinations 1 4 0 5 (9.4)
Other federal sources 0 1 1 2 (3.8)
Total 9 32 12 53 (100.0)
Abbreviations: NIH National Institutes of Health
Table 6 Repurposing agent trials between 2016 and 2020











Phase I 1 3 1 2 3 2 7 1 8 1
Phase II 10 7 11 9 15 10 19 7 28 4
Phase
III
4 3 4 4 2 5 3 6 6 6
Total 15 13 16 15 20 17 29 14 42 11
Abbreviations: DMT disease-modifying therapy
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Repurposing is to be distinguished from developing
extended indications for a proprietary agent as part of
life-cycle management. Pimavanserin, for example, is ap-
proved for the treatment of hallucinations and delusions
in Parkinson’s disease psychosis; an extended application
for dementia-related psychosis is currently being devel-
oped for several dementia syndromes [51, 52]. Likewise,
suvorexant is approved for insomnia and completed a
successful trial for insomnia in AD and the labeling of
the compound has been adjusted to include this infor-
mation. Brexpiprazole is approved for the treatment of
schizophrenia and as adjunctive therapy for major de-
pressive disorder; it is being assessed in the AD pipeline
as a therapy for agitation [53]. These programs represent
extensions of indications and not repurposing.
Repurposing can be distinguished from repositioning
in which a non-approved agent in a sponsor’s develop-
ment program changes from one indication to another
because disease-related, compound-related, or commer-
cial circumstances suggest that success in further devel-
opment may be more likely in one condition than
another [54, 55].
Limitations
There are limitations of the current analyses. Because
not all Phase I trial activity may be recorded in the clini-
caltrials.gov database, our data may underestimate the
actual number of trials in this phase. Estimates of drugs
designated as DMT versus symptomatic agents may be
equivocal depending on what is perceived as an agent’s
principle MOA. We stopped entering new data into our
database at a time that allowed submission, peer review,
and publication (final data collection stopped on Febru-
ary 27, 2020) and there may be newer trials or changes
to current trials not reflected in this document.
Conclusions
In summary, repurposing is a promising avenue for AD
drug development, comprises a substantial part of the
current AD pipeline, and is increasing in absolute num-
bers of agents and as a proportion of the pipeline. Re-
purposing may reduce drug development costs by up to
50% and accelerate times lines for progression in the
pipeline. Repurposing draws on development programs
from numerous other indications. Repurposing is an im-
portant part of the current AD drug development
ecosystem.
Abbreviations
AD: Alzheimer’s disease; AMBAR: Alzheimer’s Management by Albumin
Replacement; DMT: Disease-modifying therapy; FDA: Food and Drug
Administration; IVIG: Intravenous immunoglobulin; MCI: Mild cognitive
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Table 7 Repurposing agents currently in the European Alzheimer’s Disease development pipeline (as of February 27, 2020)
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